ACETO Corporation NASDAQ: ACET. Investor Presentation February 2018
|
|
- Fay Page
- 6 years ago
- Views:
Transcription
1 ACETO Corporation NASDAQ: ACET Investor Presentation February 218
2 Disclosure This presentation contains forward-looking statements, as defined by the Private Securities Litigation Reform Act of 1995, that can be identified by words such as believes, expects, anticipates, plans, projects, seeks and similar expressions and involve numerous risks and uncertainties. The Company s actual results could differ materially from those anticipated or implied in such forward-looking statements as a result of certain factors, as set forth in the Company s filings with the Securities and Exchange Commission. 2
3 Company Overview Human Health Pharmaceutical Ingredients Performance Chemicals Finished Dosage Form Generics (Rising Pharmaceuticals) Nutritionals Active Pharmaceutical Ingredients Pharmaceutical Intermediates Specialty Chemicals Agricultural Protection Products 3
4 Transition To Human Health Entered U.S. Finished Dosage Generics business acquiring Rising Pharmaceuticals Aurobindo for Citron products Enhanced senior management team Expanded the portfolio of commercialized and pipeline products through the acquisition of PACK Pharmaceuticals and ANDAs from PAR Pharmaceuticals SIC and GICS codes changed to reflect Healthcare Distribution Acquired certain products and assets of Citron Pharma Acquired ownership of 29 ANDA s (expanded commercial products by 5%) Aligned with world-class development & manufacturing partners 4
5 Mix Shifting Toward Human Health Sales Mix Gross Profit Mix FY 21 FY 217 (1) FY 21 FY 217 (1) 14% 47% 39% 26% 25% 49% 45% 14% 41% 26% 18% 56% $346.6 million $638.3 million $54.2 Million (Gross Margin- 15.6%) $14.8 Million (Gross Margin- 22.1%) (1) 217 includes Citron generic products and related assets from December 21, 216 (~6 months). 5
6 Human Health I n c o m e B e f o r e I n c o m e T a x e s ( $ / M ) Source: Form 1-K for fiscal year ended June 3, 217 Rising Pharmaceuticals Portfolio of 14 finished dosage form generic prescription drugs and over-the-counter products Strong brand recognition within generic pharma industry Long-standing commitment to quality, reliability and customer service Strong regulatory compliance track record Partnership model including supply contract with Aurobindo for Citron products Enhanced senior management team Nut rit ionals Filled in functional leaders in business development, commercial operations, sales and finance Nutraceutical ingredients Represent at ive Cust omers 6
7 Expanding Rising Pharmaceuticals Portfolio Commercialized Generic Products Portfolio 14 ANDAs Filed and Approved Pending Launch Products Under Development (1) January 15, January 15, FY FY FY 211 JANUARY 15, 218 ANDAs Filed Approved Pending Launch Mostly niche products with MIS sales between $5 million and $15 million Primarily oral tablets Diverse therapeutic treatments Expect to launch 15-2 products in FY 218 Optimizing portfolio for a mix of more complex, higher margin opportunities Blend of oral, topical, and sterile finished dosage forms Effectively engaging with global API network through Aceto connections Asset light model creates both flexibility and access to a wide range of dosage forms and therapeutic categories (1) Excludes 4 pipeline products associated with $5 million potential earn-out under Citron transaction 7
8 Number of Filed ANDAs IMS Value of Filed ANDAs Rising Pharmaceuticals - 36 Filed ANDAs Aging (1) Addressable Market Value of $11.7 Billion (1) (2) $6, $5, $4,83 $5, $4, $3, 6 4 $2, months months months 37+ months $1, $- $ months $ months $ months $243 $ months Months at FDA Genericized Market Ungenericized Markets Months at FDA Genericized Market Ungenericized Markets (1) As of January 15, 218 (2) Value is based on total market, including brand & generic where applicable, using recent IMS sales data 8
9 Pharmaceutical Ingredients I n c o m e B e f o r e I n c o m e T a x e s ( $ / M ) Select and source active pharmaceutical ingredients (APIs) in partnership with brand and generic drug manufacturers Source high quality pharmaceutical intermediates High level of regulatory expertise Products predominately sourced from India and China Primarily sell to customers in the U.S. and Europe Segment historically has delivered stable profitability and cash flow Represent at ive Cust omers Source: Form 1-K for fiscal year ended June 3, 217 9
10 Performance Chemicals I n c o m e B e f o r e I n c o m e T a x e s ( $ / M ) Source: Form 1-K for fiscal year ended June 3, 217 S p e c i a l t y Chemical B u s i n e s s Sourcing and distribution operating model with regulatory support Various end markets: coatings, plastics, food/beverage, ag intermediates Predominately sourced in China Consultative sales approach A g r i c u l t u r al P r o t e c tion P r o d u c t s IP ownership through technical and end use registration with EPA Warehouse and distribute finished product under the Aceto label Product categories include fungicides, insecticides and inhibitors Outsourced Active Ingredient manufacturing predominately in China S e g ment p r o vi d e s r e l i a b l e a n d s t a b l e c a s h f l o w Represent at ive Cust omers 1
11 Worldwide Presence UNITED KINGDOM GERMANY NETHERLANDS JAPAN USA Corporate HQ New York CHINA PHILIPPINES SINGAPORE FRANCE INDIA 11
12 Near Term Operational Initiatives Internal Rising Warehouse Expansion ERP update ~125,square foot facility in Somerset, NJ J a n u a r y March : in-bound freight to begin arriving March J u n e : 3PL inventory draw down End of J u n e : fully functional Currently 3 Rising B u s i n e s s Units with disparate ERP systems Acetris Health (formerly Citron s Lucid government business) Rising Health (formerly Citron business) Rising Pharma (legacy Rising business) Phased-in approach March : Acetris Health go live J u l y 1, : point of sale gross to net application go live at Rising Pharma and Rising Health simultaneously 12
13 Longer Term Whiteboard of Opportunity Rising up the generic pharma operating model value chain: Strategic vertical integration leveraging Pharma Ingredients expertise/global footprint Current State Potential Future State Asset Light Partnership Model Asset Light Partnership Model Pharma Ingredients Pharma Ingredients IP ANDAs / DMFs Manufacturing Formulation Expertise Key Take Aways Key Take Aways Minimal integration with Pharma Ingredients Bifurcated model partner with best in class Significant profit share splits with partner Margin enhancement Reliance on multiple partners to perform Leverage global Pharma Ingredients footprint and expertise IP often shared Reduce complexity/increase operational control Enterprise wide value creation 13
14 FISCAL 218 GUIDANCE (1) Net Sales Non-GAAP EPS $638.3 Million 1-15% growth $1.19 $1. - $1.5 FY 217 FY 218E FY 217 FY 218E Estimate price erosion on generic drugs in the low-double digit range Launch 15-2 products Spending ~$9 million on finished dosage generic pipeline (1) As of November 2,
15 Strong Financial Position Provides Financial Flexibility 1 Financial position at December 31, 217: Cash, cash equivalents and short-term investments of $68 million Convertible debt of $125 million Other bank debt of $22 million Working capital of $239 million Shareholders equity of $397 million 2 Strong cash flow affords an expected $.26 per share annual dividend rate and enabled debt pay down of $56M since January 1,
16 Income Statement Highlights Human Health Pharmaceutical Ingredients Performance Chemicals ($/M) ($/M) ($/M) FY 216 FY 217 1H 217 1H Revenue FY 217 FY 216 1H 217 1H 218 Gross Profit FY 216 FY 217 1H 217 1H Revenue ($/M) ($/M) ($/M) FY 216 FY 217 1H 217 1H 218 Gross Profit FY 216 FY 217 1H 217 1H Revenue FY 216 FY 217 1H 217 1H 218 Gross Profit 16
17 Investment Highlights Steadily transitioning toward Human Health Rising Pharmaceuticals is a platform for higher-margin finished dosage form generics Track record of 5 consecutive years of dividend payments, providing return to shareholders Asset-light business model generates strong free cash flow Strong cash generation to support debt reduction and growth initiatives 17
18 NASDAQ:ACET International company engaged in the marketing, sale and distribution of Human Health products, Pharmaceutical Ingredients and Performance Chemicals Aceto Headquarters: 4 Tri Harbor Court Port Washington, New York 115 For additional information please contact: Jody Burfening LHA Investor Relations 8 3rd Avenue, 17th Fl. New York, NY 122 Tel: jburfening@lhai.com Social Media: Linkedin.com/company/aceto-corporation 18
ACETO Corporation NASDAQ: ACET. Update May 2018
ACETO Corporation NASDAQ: ACET Update May 218 Disclosure This presentation contains forward-looking statements, as defined by the Private Securities Litigation Reform Act of 1995, that can be identified
More informationAceto Corporation. NASDAQ: ACET Investor Update November 2018
Aceto Corporation NASDAQ: ACET Investor Update November 2018 Disclosure This presentation contains forward-looking statements, as defined by the Private Securities Litigation Reform Act of 1995, that can
More informationACETO Corporation. June 8, 2016
NASDAQ:ACET ACETO Corporation Jefferies Healthcare Conference June 8, 2016 Sourcing & Supplying Quality Products Worldwide Disclosure This presentation contains forward-looking statements, as defined by
More informationAcquisition of Generic Drug-Related Assets of Citron Pharma and Lucid Pharma
NASDAQ: ACET ACETO Corporation Acquisition of Generic Drug-Related Assets of Citron Pharma and Lucid Pharma November 3, 2016 Disclosure This presentation contains forward-looking statements, as defined
More informationAkorn, Inc. N a s d a q : A K R X
Akorn, Inc. N a s d a q : A K R X Jefferies 2014 Global Healthcare Conference June 2014 DISCLAIMER This presentation includes certain forward-looking statements regarding our views with respect to our
More informationJUBILANT LIFE SCIENCES Q4 & FY2016 RESULTS
PRESS RELEASE Noida, Tuesday, May 24, 2016 Jubilant Life Sciences Ltd. 1A, Sector 16A, Noida 201301, India Tel.: +91 120 4361000 http://www.jubl.com JUBILANT LIFE SCIENCES Q4 & FY2016 RESULTS JUBILANT
More informationJUBILANT LIFE SCIENCES Q2 & H1 FY19 RESULTS
PRESS RELEASE Noida, Monday, Oct 22, 2018 Jubilant Life Sciences Ltd. 1A, Sector 16A, Noida 201301, India Tel.: +91 120 4361000 http://www.jubl.com JUBILANT LIFE SCIENCES Q2 & H1 FY19 RESULTS JUBILANT
More informationJUBILANT LIFE SCIENCES Q2/H1 FY2018 RESULTS
PRESS RELEASE Noida, Saturday, Oct 28, 2017 Jubilant Life Sciences Ltd. 1A, Sector 16A, Noida 201301, India Tel.: +91 120 4361000 http://www.jubl.com JUBILANT LIFE SCIENCES Q2/H1 FY2018 RESULTS The Board
More informationJUBILANT LIFE SCIENCES Q4/FY2017 RESULTS
PRESS RELEASE Noida, Tuesday, May 23, 2017 Jubilant Life Sciences Ltd. 1A, Sector 16A, Noida 201301, India Tel.: +91 120 4361000 http://www.jubl.com JUBILANT LIFE SCIENCES Q4/FY2017 RESULTS JUBILANT REPORTS
More informationAkorn, Inc. N a s d a q : A K R X
Akorn, Inc. N a s d a q : A K R X Jefferies 2014 Global London Healthcare Conference November 2014 DISCLAIMER This presentation includes certain forward-looking statements regarding our views with respect
More informationLupin Investor Presentation Q3FY14
Lupin Investor Presentation Q3FY14 Vision: To be an innovation led transnational company Safe harbor statement Materials and information provided during this presentation may contain forward looking statements.
More information34 th Annual J.P. Morgan Healthcare Conference. Steve Collis, President & CEO Tim Guttman, EVP & CFO
34 th Annual J.P. Morgan Healthcare Conference Steve Collis, President & CEO Tim Guttman, EVP & CFO January 12, 2016 Steve Collis President & CEO Cautionary Note Regarding Forward-Looking Statements Certain
More informationJefferies Global Healthcare Conference
Jefferies Global Healthcare Conference June 7, 2012 2012 PAREXEL International Safe Harbor This presentation contains forward-looking statements within the meaning of Section 27A of the Securities Act
More informationLUPIN LIMITED. Q3 FY18 Investor Presentation. February 06, 2018
LUPIN LIMITED Q3 FY18 Investor Presentation February 06, 2018 Safe Harbor Statement Materials and information provided during this presentation may contain forward-looking statements. These statements
More informationACETO CORPORATION (Exact name of registrant as specified in its charter)
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15 (d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended
More informationThird quarter 2011 Adjusted EBITDA was $11.9 million, up 88% compared with $6.3 million in the comparable prior year quarter.
At the Company: Akorn, Inc. Tim Dick, Chief Financial Officer (847) 279-6150 FOR IMMEDIATE RELEASE Akorn Reports Record Third Quarter 2011 Financial Results -Revenues of $36.67 million or a 69% increase
More informationInvestor Relations Presentation. Delivering solutions, shaping the future
Investor Relations Presentation Delivering solutions, shaping the future Our Story Leader Differentiator Consistency Decades of experience Leading the dispensing solutions niche of the packaging industry
More informationAnnual General Meeting July 20, 2017
Annual General Meeting July 20, 2017 Forward Looking Statements Certain statements in this presentation are "forward-looking statements." These statements relate to future events or the Company's future
More informationAkorn Reports First Quarter 2013 Financial Results - Reports Record Revenue of $73.9 million and Adjusted EPS of $0.13-
At the Company: Akorn, Inc. Tim Dick, Chief Financial Officer (847) 279-6150 FOR IMMEDIATE RELEASE Akorn Reports First Quarter 2013 Financial Results - Reports Record Revenue of $73.9 million and Adjusted
More informationIndian Pharmaceutical Formulations Industry Report,
Indian Pharmaceutical Formulations Industry Report, 2008-2009 India plays an important role in the global pharmaceutical market. In 2005, 2/5 DMFs to FDA were submitted by India. Currently, there are more
More informationIMPAX LABORATORIES INC
IMPAX LABORATORIES INC FORM 8-K (Current report filing) Filed 02/20/14 for the Period Ending 02/20/14 Address 30831 HUNTWOOD AVENUE HAYWARD, CA 94544 Telephone 510-240-6000 CIK 0001003642 Symbol IPXL SIC
More informationQ3 FY09 Results Update
Q3 FY09 Results Update January 20, 2009 1 Safe Harbor Statement This presentation contains forward-looking statements and information that involve risks, uncertainties and assumptions. Forward-looking
More informationJUBILANT LIFE SCIENCES Q4 & FY2016 RESULTS
PRESS RELEASE Noida, Tuesday, May 24, 2016 Jubilant Life Sciences Ltd. 1A, Sector 16A, Noida 201301, India Tel.: +91 120 4361000 http://www.jubl.com JUBILANT LIFE SCIENCES Q4 & FY2016 RESULTS JUBILANT
More informationHIKMA PHARMACEUTICALS PLC UBS GLOBAL GENERIC & SPECIALITY PHARMACEUTICALS CONFERENCE NEW YORK 8-9 MAY 2007
HIKMA PHARMACEUTICALS PLC UBS GLOBAL GENERIC & SPECIALITY PHARMACEUTICALS CONFERENCE NEW YORK 8-9 MAY 2007 About Hikma Founded in Jordan in 1978 Multinational business developing, manufacturing and marketing
More informationFor personal use only
MAYNE PHARMA ANNOUNCES ACQUISITION OF US GENERIC PRODUCT PORTFOLIO FROM TEVA AND ALLERGAN NOT FOR DISTRIBUTION OR RELEASE IN THE UNITED STATES 28 June 2016, Adelaide, South Australia Mayne Pharma Group
More informationLannett Company, Inc. Kremers Urban Acquisition September 2, 2015
Lannett Company, Inc. Kremers Urban Acquisition September 2, 2015 Forward Looking Statements Except for historical facts, the statements in this presentation, as well as oral statements or other written
More informationStrides Pharma, Inc. Consolidated Financial Statements. March 31, With Independent Auditors Report
Consolidated Financial Statements With Independent Auditors Report Table of Contents Page(s) Independent Auditors Report... 1 Consolidated Financial Statements Consolidated Balance Sheet... 2 Consolidated
More informationAurobindo Pharma Limited Presentation to Investors
Aurobindo Pharma Limited Presentation to Investors February 2013 Forward looking statement This presentation contains statements that constitute forward looking statements including and without limitation,
More informationCitigroup 14 th Annual High Yield / Leveraged Finance Conference
FMC Corporation Citigroup 14 th Annual High Yield / Leveraged Finance Conference March 7, 2005 Thomas C. Deas, Jr. Vice President & Treasurer Disclaimer Safe Harbor Statement under the Private Securities
More informationInnophos Holdings, Inc. May 2018
Innophos Holdings, Inc. May 2018 Forward-Looking Statements This presentation contains or may contain forward-looking statements within the meaning of Section 27a of the Securities Act of 1933, as amended,
More informationLUPIN LIMITED. Q2 FY17 Investor Presentation November 09, Aerial view of Lupin offices, Baltimore, US
LUPIN LIMITED Q2 FY17 Investor Presentation November 09, 2016 Safe Harbor Statement This report contains forward-looking statements that involve known and unknown risks, uncertainties and other factors
More informationViews on the Generics Market
Views on the Generics Market Dr Brian Tempest Chief Mentor & Executive Vice Chairman of the Board Ranbaxy Laboratories, Delhi, India EGA Conference Istanbul, Turkey 15 th June 2007 Safe Harbor Except for
More informationWest Pharmaceutical Services, Inc. June 2016
West Pharmaceutical Services, Inc. June 2016 Safe harbor statement Cautionary Statement Under the Private Securities Litigation Reform Act of 1995 This slide presentation and any accompanying management
More informationIndian Active Pharmaceutical Ingredients (APIs) Industry Report,
Indian Active Pharmaceutical Ingredients (APIs) Industry Report, 2008-2009 India plays an important part in the global API market. The API output value of India was US $4.1 billion in 2007, with the CAGR
More informationAkorn Reports Second Quarter 2011 Financial Results -Revenues of $32.1 million and Adjusted EBITDA of $10.6 million- -Raises Outlook for 2011-
At the Company: Akorn, Inc. Tim Dick, Chief Financial Officer (847) 279-6150 FOR IMMEDIATE RELEASE Akorn Reports Second Quarter 2011 Financial Results -Revenues of $32.1 million and Adjusted EBITDA of
More informationACETO CORP (ACET) 10-Q
ACETO CORP (ACET) 10-Q Quarterly report pursuant to sections 13 or 15(d) Filed on 11/06/2009 Filed Period 09/30/2009 UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q QUARTERLY
More informationInstitutional Presentation. June/2016
V2 Institutional Presentation June/2016 Disclaimer This release contains forward-looking statements that are exclusively related to the prospects of the business, its operating and financial results, and
More informationFinancial Results Quarter Ended December 31, 2015
Financial Results Quarter Ended December 31, 2015 Disclaimer Statements in this document relating to future status, events, or circumstances, including but not limited to statements about plans and objectives,
More informationIMPAX LABORATORIES INC
IMPAX LABORATORIES INC FORM 8-K (Current report filing) Filed 05/11/15 for the Period Ending 05/11/15 Address 30831 HUNTWOOD AVENUE HAYWARD, CA 94544 Telephone 510-240-6000 CIK 0001003642 Symbol IPXL SIC
More informationFOSSIL GROUP, INC. REPORTS FIRST QUARTER FISCAL 2015 RESULTS; First Quarter Net Sales of $725 Million; Diluted EPS of $0.75
FOSSIL GROUP, INC. REPORTS FIRST QUARTER FISCAL 2015 RESULTS; First Quarter Net Sales of $725 Million; Diluted EPS of $0.75 Maintains Full Year Constant Currency Guidance and Provides Second Quarter Guidance
More informationCase M TEVA/ALLERGAN GENERICS
EUROPEAN COMMISSION DG Competition Case M. 7746 TEVA/ALLERGAN GENERICS Only the English text is available and authentic. REGULATION (EC) No 139/2004 MERGER PROCEDURE Decision on the implementation of remedies
More informationCambrex to Acquire Halo Pharma. July 23, 2018
Cambrex to Acquire Halo Pharma July 23, 2018 Forward-Looking Statements Statements in this presentation regarding the acquisition of Halo Pharma ( Halo ) and expected benefits therefrom (including revenue
More informationAurobindo Pharma Limited. Presentation to Investors
Aurobindo Pharma Limited Presentation to Investors November 2013 Forward looking statement This presentation contains statements that constitute forward looking statements including and without limitation,
More informationLonza Ltd Muenchensteinerstrasse 38 CH-4002 Basel, Switzerland
News Release Lonza Reports Strong Momentum with Organic Growth of 8% Sales and 11% CORE EBITDA in H1 2018 Double-Digit Organic Sales Growth for Businesses Along the Healthcare Continuum Outperformance
More informationPerrigo Fiscal Fourth Quarter Conference Call August 18, 2009
Perrigo Fiscal Fourth Quarter Conference Call August 18, 2009 Forward Looking Statements Certain statements in this presentation are forward-looking statements within the meaning of Section 21E of the
More informationMayne Pharma Group Limited
Mayne Pharma Group Limited HY14 Results Presentation 26 February 2014 Scott Richards, Chief Executive Officer Mark Cansdale, Group CFO Disclaimer The information provided is general in nature and is in
More informationStericycle Investor Presentation Q NASDAQ: SRCL
Stericycle Investor Presentation Q3-2017 NASDAQ: SRCL Forward - Looking Statements Safe Harbor Statement: This press release may contain forward-looking statements that involve risks and uncertainties,
More informationDr Reddy s Laboratories Ltd. Q4 FY07 and FY07 Financial Performance Review
Dr Reddy s Laboratories Ltd. NYSE:RDY Q4 and Financial Performance Review Table of Contents USGAAP Financial Snapshot 02 Revenue Mix 03 Active Pharmaceutical Ingredients 04 Generic Formulations 05 Branded
More informationQ4 & Full Year FY2018 Financial Results. November 6, 2018
Q4 & Full Year FY2018 Financial Results November 6, 2018 Cautionary Note Regarding Forward-Looking Statements Certain of the statements contained in this presentation are forward-looking statements within
More informationINVESTOR BRIEFING. March 2013
INVESTOR BRIEFING March 2013 Safe Harbor Statement This presentation includes forward-looking statements within the meaning of the Safe Harbor provisions of the Securities Litigation Reform Act of 1995.
More informationQ4 and Full Year 2018 Earnings Call
We make healthy possible Q4 and Full Year 2018 Earnings Call Financial Results and Business Update February 28, 2019 Safe Harbor Statement Safe Harbor Statement Certain statements contained herein, regarding
More informationLife Sciences and Materials Sciences. DSM in motion: driving focused growth
Life Sciences and Materials Sciences DSM in motion: driving focused growth Nico Gerardu Member of the Managing Board Particuliere Aandeelhouders, Urmond/Geleen 19 November 2010 Safe Harbor Statement This
More informationInvestor Presentation
Investor Presentation www.ajantapharma.com 1 BSE Symbol : AJANTAPH Code: 532331 NSE Symbol : AJANTPHARM ISIN: INE031B01031 Safe Harbour Statement This presentation may include certain forward looking statements,
More informationFinancial Targets through 2022: Focus on Value Creation
Financial Targets through 2022: Focus on Value Creation /////////// Capital Markets Day London, December 5, 208 Wolfgang Nickl CFO Bayer AG Disclaimer Cautionary Statements Regarding Forward-Looking Information
More informationBank of America Leveraged Finance Conference JOHN CHIMINSKI PRESIDENT & CEO
Bank of America Leveraged Finance Conference JOHN CHIMINSKI PRESIDENT & CEO Forward Looking Statements This presentation contains both historical and forward-looking statements. All statements other than
More information37 th Annual JP Morgan Healthcare Conference. January 8, 2019
37 th Annual JP Morgan Healthcare Conference January 8, 2019 Safe Harbor Statement This presentation contains forward-looking statements and information that involve risks, uncertainties and assumptions.
More informationSiegfried with Sales and Margin Growth
Media Release Zofingen, 14 March 2018 Siegfried with Sales and Margin Growth The Siegfried Group reported sales of 750.5 million francs for the 2017 financial year, corresponding to a growth of 4.6% Earnings
More informationLupin 1QFY2018 Result Update
Jul-12 Nov-12 Mar-13 Jul-13 Nov-13 Mar-14 Jul-14 Nov-14 Mar-15 Jul-15 Nov-15 Mar-16 Jul-16 Nov-16 Mar-17 Jul-17 1QFY2018 Result Update Pharmaceutical August 07, 2017 Lupin Performance Highlights Y/E March
More informationInvestor Presentation
Aurobindo Pharma Limited Investor Presentation Investor Presentation August 2015 May 2015 Forward looking statement This presentation contains statements that constitute forward looking statements including
More informationDr Reddy s Laboratories Ltd. Q1 FY05 Financial Performance Review
Dr Reddy s Laboratories Ltd. NYSE:RDY Financial Performance Review Table of Contents USGAAP Financial Snapshot 02 Revenue Mix 03 Active Pharmaceutical Ingredients 04 Generic Formulations 04 Branded Formulations
More informationIntellipharmaceutics Announces First Quarter 2018 Results
April 16, 2018 Intellipharmaceutics Announces First Quarter 2018 Results TORONTO, ON / ACCESSWIRE / April 16, 2018 / Intellipharmaceutics International Inc. (NASDAQ: IPCI and TSX: IPCI) ("Intellipharmaceutics"
More informationFMC Corporation Announces Acquisition of Significant Portion of DuPont s Crop Protection Business; Simultaneous Sale of Health and Nutrition to DuPont
FMC Corporation Announces Acquisition of Significant Portion of DuPont s Crop Protection Business; Simultaneous Sale of Health and Nutrition to DuPont March 31, 2017 As Prepared for Delivery Introduction
More informationFourth Quarter and Full Year 2017 Results. March 1, 2018
1 Fourth Quarter and Full Year 2017 Results March 1, 2018 Impax Cautionary Statement Regarding Forward Looking Statements 2 "Safe Harbor" statement under the Private Securities Litigation Reform Act of
More informationStericycle, Inc. Q NASDAQ: SRCL
Stericycle, Inc. Q3 2015 NASDAQ: SRCL Forward - Looking Statements This presentation may contain forward-looking statements that involve risks and uncertainties, some of which are beyond our control (for
More informationDear Fellow Shareholders On behalf of the Board of Directors, I take pleasure in welcoming all of you to the 17 th AGM of your company.
Text of the speech delivered by Mr. Dilip Shanghvi, Chairman and Managing Director of the Sun Pharmaceutical Industries Ltd., at the 17 th Annual general meeting of the company held on Sept 11, 2009 in
More informationStrong Margins, Robust Profitability Quarter I Results, FY EBITDA up 44%, Net profit up 43%
Strong Margins, Robust Profitability Quarter I Results, FY 2013 14 EBITDA up 44%, Net profit up 43% Mumbai, Aug 7, 2013: Pharma Major, Lupin Ltd. reported its performance for the first quarter ending 30
More informationPress Release. Consolidated Financial & Performance Highlights (Pharma & Biotech)
Press Release Strides Shasun announces Q1 FY17 results Q1 FY17 Pharma Revenues* at INR 8,699 Mn, Growth of 43% YoY, Pharma EBITDA at INR 1,451 Mn, Growth of 57% YoY Bengaluru, August 17, 2016: Strides
More informationJ.P. Morgan Healthcare Conference
J.P. Morgan Healthcare Conference Alistair Macdonald Chief Executive Officer January 8, 2019 Forward-Looking Statements, Non-GAAP Financial Measures, and Basis of Financial Presentation Forward-Looking
More informationInvestor Presentation February 2019
Investor Presentation February 2019 Dr. Reddy s Laboratories Limited Hyderabad, India BSE: 500124 NSE: DRREDDY NYSE: RDY Safe Harbor Statement This presentation contains forward-looking statements and
More informationPresentation of the 2011 results
Presentation of the 2011 results 22 February 2012 PCAS mission statement To offer the best response to the global challenges and specific expectations of our clients with secure, competitive, innovative
More informationQ EARNINGS CALL July 30, :00 am ET
Q2 2018 EARNINGS CALL July 30, 2018 9:00 am ET Forward-Looking Statements This presentation contains or may contain forward-looking statements within the meaning of Section 27a of the Securities Act of
More informationDr. Reddy s Q1 FY19 Financial Results
Press Release DR. REDDY'S LABORATORIES LTD. 8-2-337, Road No. 3, Banjara Hills, Hyderabad - 500034. Telangana, India. INVESTOR RELATIONS SAUNAK SAVLA saunaks@drreddys.com (Ph: +91-40-4900 2135) CONTACT
More informationInvestor Presentation. March 2016
Investor Presentation March 2016 Safe Harbor Statement This presentation includes forward-looking statements (statements which are not historical facts) within the meaning of the Private Securities Litigation
More informationEDGAR Submission Header Summary
EDGAR Submission Header Summary Submission Type 10-Q Live File Return Copy Exchange Confirming Copy on on NASD off Filer CIK 0000002034 Filer CCC xxxxxxxx Period of Report 03/31/13 Smaller Reporting Company
More informationPRESS RELEASE. 13 September 2018 Aspen One
PRESS RELEASE Aspen Pharmacare Holdings Limited ( Aspen ) (Incorporated in the Republic of South Africa) (Registration Number 1985/002935/06) (Share code APN ISIN: ZAE000066692) 13 September 2018 Aspen
More informationFinancial Results Analysis Quarter & 9 Months Ended December 31, 2011
Financial Results Analysis Quarter & 9 Months Ended December 31, 2011 Disclaimer 1 Statements in this document relating to future status, events, or circumstances, including but not limited to statements
More informationRaymond James 38 th Annual Institutional Investor Conference. March 6, 2017
Raymond James 38 th Annual Institutional Investor Conference March 6, 2017 1 Impax Cautionary Statement Regarding Forward Looking Statements "Safe Harbor" statement under the Private Securities Litigation
More informationBusiness Plan FEBRUARY 2013
Business Plan 2013 2015 12 FEBRUARY 2013 Company development, recent history Euro millions 900 800 700 600 500 400 300 200 100 0 180 160 140 120 100 80 60 40 20 0 Sales Gross profit CAGR 6.9% CAGR 4.8%
More informationInnophos Holdings, Inc. Reports Fourth-Quarter and Full-Year 2018 Results
Innophos Holdings, Inc. Reports Fourth-Quarter and Full-Year 2018 Results February 20, 2019 Delivered Top and Bottom Line Results in Line with Expectations Double Digit Year-on-Year Revenue Growth in 2018
More informationAnnual Shareholder Meeting. Joachim Kreuzburg Chairman of the Board and CEO 03. April 2018
Annual Shareholder Meeting Joachim Kreuzburg Chairman of the Board and CEO 03. April 2018 Disclaimer This presentation contains statements concerning Sartorius Stedim Biotech Group s future performance.
More informationForward-Looking Statements. Consolidated Financial Results for the 3rd Quarter of Fiscal Year François-Xavier Roger Chief Financial Officer
Consolidated Financial Results for the 3rd Quarter of Fiscal Year 2014 François-Xavier Roger Chief Financial Officer February 5, 2015 Forward-Looking Statements This presentation contains forward-looking
More informationINNOPHOS HOLDINGS, INC. REPORTS FOURTH-QUARTER AND FULL-YEAR 2017 RESULTS
FOR IMMEDIATE RELEASE Investor Contact Media Contact Mark Feuerbach Ryan Flaim Innophos Sharon Merrill Associates 609-366-1204 617-542-5300 investor.relations@innophos.com iphs@investorrelations.com INNOPHOS
More informationCommercial and Consumer Fine Papers. Filtration. Premium Packaging. Digital Transfer Media. Paper Gift Cards & Packaging. Backings (Tape & Abrasives)
v Filtration Commercial and Consumer Fine Papers Premium Packaging Digital Transfer Media Backings (Tape & Abrasives) Paper Gift Cards & Packaging High End Spirits Labels Other Performance Materials (Labels,
More informationInnophos Holdings, Inc. Reports Fourth-Quarter and Full-Year 2017 Results
Innophos Holdings, Inc. Reports Fourth-Quarter and Full-Year 2017 Results February 21, 2018 Significant Progress Advancing Vision 2022 Strategy 2017 Revenue and Earnings In-Line with Expectations Sets
More informationData. Insights. Results.
Image Area Data. Insights. Results. Raymond James 26 th Annual Institutional Investors Conference March 2005 Safe Harbor Certain statements we make today are forward-looking within the meaning of US federal
More informationIntellipharmaceutics Announces Second Quarter 2018 Results
July 16, 2018 Intellipharmaceutics Announces Second Quarter 2018 Results TORONTO, ON / ACCESSWIRE / July 16, 2018 / Intellipharmaceutics International Inc. (NASDAQ: IPCI and TSX: IPCI) ("Intellipharmaceutics"
More informationSteve Martens VP Investor Relations FY13 Q3
Steve Martens VP Investor Relations steve.martens@molex.com FY13 Q3 Forward-Looking Statement Statements in this presentation that are not historical are forward-looking and are subject to various risks
More informationChief Executive Officer
Said Darwazah Chief Executive Officer 211 highlights Strong Group performance in a challenging year 95 9 MSI PROMOPHARM $11.2 m $918.m 85 8 75 BRANDED + 9.6% $37.9 m INJECTABLES + 23.3% $36.7 m GENERICS
More informationHikma Pharmaceuticals PLC
Hikma Pharmaceuticals PLC This document, which has been issued by Hikma Pharmaceuticals PLC (the Company ), comprises the written materials/slides for a presentation. This document and its contents are
More informationINNOPHOS HOLDINGS, INC. REPORTS SECOND-QUARTER 2017 RESULTS. Q2 Revenue and Earnings Performance Exceeds Guidance
FOR IMMEDIATE RELEASE Investor Contact Media Contact Mark Feuerbach Ryan Flaim Innophos Sharon Merrill Associates 609-366-1204 617-542-5300 investor.relations@innophos.com iphs@investorrelations.com INNOPHOS
More informationCorn Products International, Inc.
Corn Products International, Inc. To Acquire National Starch for $1.3 Billion in Cash; Creates $5 Billion Global Ingredients Company June 21, 2010 Ilene Gordon Chairman, President, and CEO Cheryl K. Beebe
More informationBaird Global Healthcare Conference
Baird Global Healthcare Conference Jason Meggs Chief Financial Officer September 6, 2018 Forward-Looking Statements, Non-GAAP Financial Measures, and Basis of Financial Presentation Forward-Looking Statements
More informationJubilant Life Sciences Q4 & FY 2014 Earnings Conference Call Transcript May 26, 2014
Jubilant Life Sciences Q4 & FY 2014 Earnings Conference Call Transcript May 26, 2014 Ravi Agrawal: Thank you. A very good evening to you all. I am Ravi Agrawal Head of Investor Relations at Jubilant Life
More informationTEVA REPORTS FOURTH QUARTER AND FULL YEAR 2018 FINANCIAL RESULTS. Revenues $18.9 billion $4.6 billion
TEVA REPORTS FOURTH QUARTER AND FULL YEAR 2018 FINANCIAL RESULTS FY 2018 Q4 2018 Revenues $18.9 billion $4.6 billion Cash flow from operations $2.4 billion $0.4 billion GAAP loss per share $2.35 $2.85
More information2014 Investor Forum. Joe Harlan Chief Commercial Officer and Vice Chairman, Market Businesses November 13, Dow.com
2014 Investor Forum Joe Harlan Chief Commercial Officer and Vice Chairman, Market Businesses November 13, 2014 Dow.com SEC Disclosure Rules Some of our comments today include statements about our expectations
More informationFourth-Quarter and Full-Year 2016 Financial Results. Mark Costa, Board Chair & CEO Curt Espeland, EVP & CFO January 27, 2017
Fourth-Quarter and Full-Year 2016 Financial Results Mark Costa, Board Chair & CEO Curt Espeland, EVP & CFO January 27, 2017 Forward-looking statements During this presentation, we make certain forward-looking
More informationOur Transformation Continues. March 21, 2018
Our Transformation Continues March 21, 2018 Disclosure Regarding Forward-Looking Statements Forward-Looking Statements and Factors That May Affect Future Results: Throughout this presentation, we make
More informationINDOCO REMEDIES LIMITED MANAGEMENT DISCUSSION & ANALYSIS FOR THE FIRST QUARTER FY16. Apr Mar. 15 Net Sales : Jan. 15 Mar. 15
INDOCO REMEDIES LIMITED MANAGEMENT DISCUSSION & ANALYSIS FOR THE FIRST QUARTER FY16 Financials (` In Lacs) Unaudited Audited Particulars Quarter Ended Year Ended Apr. 15 Jun. 15 Jan. 15 Mar. 15 Apr. 14
More informationNorthern Technologies International Corporation. Fiscal 2019 First Quarter Investor Presentation
Northern Technologies International Corporation Fiscal 2019 First Quarter Investor Presentation Forward Looking Statements Statements contained in this presentation that are not historical information
More informationAccelerating our IPT strategy
Accelerating our IPT strategy GlaxoSmithKline plc and Pfizer Inc to form new world-leading Consumer Healthcare Joint Venture Transaction lays foundation for separation of GSK to create two new UK-based
More information